PXD101

Known as: PXD 101 
A novel hydroxamic acid-type histone deacetylase (HDAC) inhibitor with antineoplastic activity. PXD101 targets HDAC enzymes, thereby inhibiting tumor… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2003-2018
0520032018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
The primary objective of this sub-study, undertaken as an extension to the previously reported phase-I study, was to explore the… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
Is this relevant?
2009
2009
The activity of the histone deacetylase inhibitor PXD101 was investigated in three hepatocellular carcinoma (HCC) cell lines… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2009
Highly Cited
2009
BACKGROUND Belinostat (PXD 101) is a novel inhibitor of class I and II histone deacetylases. This class of compounds has… (More)
Is this relevant?
Highly Cited
2008
Highly Cited
2008
PURPOSE To determine the safety, dose-limiting toxicity, maximum tolerated dose, and pharmacokinetic and pharmacodynamic profiles… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
Is this relevant?
2007
2007
Treatment options for patients with recurrent superficial bladder cancer are limited, necessitating aggressive exploration of new… (More)
  • figure 3
  • table 1
  • table 2
Is this relevant?
Highly Cited
2007
Highly Cited
2007
Clinical trials have shown the high anti-myeloma activity of the proteasome inhibitor bortezomib. The present study examined the… (More)
Is this relevant?
2007
2007
Histone deacetylase inhibitors (HDI) can inhibit proliferation and enhance apoptosis in a wide range of malignancies. However… (More)
Is this relevant?
Highly Cited
2006
Highly Cited
2006
Histone deacetylase inhibitors represent a promising new class of anticancer agents. In the current investigation, we examined… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2006
2006
Histone deacetylase inhibitors (HDACi) inhibit the growth of cancer cells, and combinations of HDACi with established… (More)
  • table 1
  • figure 2
  • figure 1
  • figure 3
  • figure 5
Is this relevant?
Highly Cited
2003
Highly Cited
2003
Histone acetylation has a central role in the control of gene expression, influencing transcriptional control of many genes… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?